<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02866682</url>
  </required_header>
  <id_info>
    <org_study_id>14-001423</org_study_id>
    <nct_id>NCT02866682</nct_id>
  </id_info>
  <brief_title>A Phase 4, Open Label Multi-Center, Prospective, Randomized Study of Comparing the Efficacy and Safety of Generic vs. Brand Tacrolimus on Kidney Transplant Outcomes in De Novo in Kidney, Heart and Liver Transplant Recipients</brief_title>
  <official_title>Prospective Study Comparing Brand and Generic Immunosuppression on Transplant Outcomes, Adherence, &amp; Immune Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Food and Drug Administration (FDA)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      As the patents for brand-name immunosuppressive medications expire, there is increasing
      interest in using generic immunosuppressive drugs. However, despite pharmacokinetic studies
      showing bioequivalence, questions remain regarding the clinical impact of use of generic
      immunosuppression.

      The most important immunosuppressive agent in the modern transplant era is arguably
      tacrolimus, a calcineurin-inhibitor with a narrow therapeutic index. This study seeks to
      answer the question regarding the clinical impact of generic tacrolimus use as measured
      primarily by acute rejection, loss of graft function, and patient death through a randomized
      trial of 4 parallel groups: Brand tacrolimus only, brand tacrolimus for 6 months than switch
      to Generic A, Generic A only, or Generic A for 6 months than switch to any other generic
      tacrolimus. Given that kidney, liver, and heart transplantation are the most commonly
      performed transplants with well-defined measures of rejection and graft failure, these organs
      will be studied in a two-center study designed to accrue the target number of transplant
      recipients within the three-year study period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, randomized, open-label, multicenter, parallel, observational study to assess
      safety and efficacy of 300 kidney, heart and liver transplant recipients comparing brand
      tacrolimus to generic and a combination of generic and brand tacrolimus over the three year
      follow up period. All subjects will receive other immunosuppressive medications including
      induction therapy (thymoglobulin, basiliximab, or no induction) and maintenance including
      mycophenolate mofetil and corticosteroid therapy as directed by standard-of-care at each
      center. Their medication information will be recorded in their study files.

      The study population includes recipients of kidney, liver, or heart allografts in the first
      14 days after transplantation.

      The totals of 15 visits over 36 months period are planned as follows. The blood samples
      specified below are for the translational research study labs. Subjects will continue to
      receive routine labs as part of their standard of care from their treating physician. For
      detailed information about the study labs schedule see Table 5 Study Schedule, and for the
      study safety labs by organ see Appendix 4. These safety labs are done as part of their stand
      of care from their treating physician.

      If the subject needs more study drug medication before his or her next study visit the
      subject will come in to the clinic to get a new supply.

      First (Baseline) Visit (up to 14 days after transplant but before the study subject is
      discharged from the hospital):

        -  Subject reviews and signs consent form

        -  Review of subject's medical history

        -  Review of subject's current medications

        -  Review of subject's physical exam including vital signs (blood pressure, temperature,
           pulse and respiration rate), height and weight

        -  Review of any changes in subject's health and any reactions to the study medication will
           be recorded

        -  About 16 cc blood sample (about 3.2 teaspoons of blood) will be collected from the
           subject for translational research study laboratory tests

        -  Randomization of subject

        -  Subject will receive study drug.

      Month 1 Visit:

        -  Review of subject's current medications

        -  Review of subject's physical exam including vital signs (blood pressure, temperature,
           pulse and respiration rate), height and weight

        -  Review of any changes in subject's health and any reactions to the study medication will
           be recorded

        -  Subject returns completed dosing diary and receives new dosing diary

        -  Subject will receive study drug.

      Month 2/3 Visit:

        -  Review of subject's current medications

        -  Review of subject's physical exam including vital signs (blood pressure, temperature,
           pulse and respiration rate), height and weight

        -  Review of any changes in subject's health and any reactions to the study medication will
           be recorded

        -  About 16 cc blood sample (about 3.2 teaspoons of blood) will be collected from the
           subject for translational research study laboratory tests (Month 3 Visit only)

        -  Subject returns completed dosing diary and receives unfilled dosing diary

        -  Subject will receive study drug.

      Month 6/9/12/24 Visit:

        -  Review of subject's current medications

        -  Review of subject's physical exam including vital signs (blood pressure, temperature,
           pulse and respiration rate), height and weight

        -  Review of any changes in subject's health and any reactions to the study medication will
           be recorded

        -  About 32 cc blood sample (about 6.5 teaspoons of blood) (Month 6 Visit only) and about
           16 cc (about 3.2 teaspoons) for Month 9, 12 and 24 will be collected from the subject
           for translational research study laboratory tests

        -  Subject returns completed dosing diary and receives unfilled dosing diary

        -  Subject will receive study drug if applicable.

        -  If in Group 4 the subject will be receiving immunosuppressant drug from his or her local
           pharmacy

      Month 15/21/27/33 Visit:

        -  Subject will receive study drug if applicable

        -  If in Group 4 the subject will be receiving immunosuppressant drug from his or her local
           pharmacy

        -  If in Group 4 and the subject is not coming to the clinic for his or her study visit the
           subject will receive a CleverCap and dosing diary by mail. The subject will also receive
           instructions on how to mail back the old CleverCap and dosing diary.

      Month 18/30 Visit:

        -  Review of subject's current medications

        -  Review of any changes in subject's health and any reactions to the study medication will
           be recorded

        -  Subject returns completed dosing diary and receives unfilled dosing diary

        -  Subject will receive study drug if applicable.

        -  If in Group 4 the subject will be receiving immunosuppressant drug from his or her local
           pharmacy

      Month 36 Visit (End of Study Visit):

        -  Review of subject's current medications

        -  Review of any changes in subject's health and any reactions to the study medication will
           be recorded

        -  About 16 cc blood sample (about 3.2 teaspoons of blood) will be collected from subject
           for translational research studies laboratory tests

        -  Subject returns final completed dosing diary

        -  Subject returns any study drug remaining in his or her possession to the study team A
           safety follow-up phone call will be made at month 37 (+/- I week) to record patient's
           wellbeing and graft survival. This call will serve as the last AE follow-up if any was
           reported at month 36.

      Total blood 32 cc of blood (approximately 6.5 teaspoons) will be drawn from the subject at
      Month 6 study visit. At Baseline, Month 3, Month 9, Month 12, Month 24 and Month 36 study
      visits the subject will have drawn about 16 cc (approximately 3.2 teaspoons) of blood. During
      the course of the study (after approximately 3 years of participation in the study), the
      total amount of blood that will be drawn is approximately 128 cc (approximately 8.7
      tablespoons or 1/2 cup). This is about a third of the amount usually drawn when someone
      donates a pint of blood. Also, the subject will continue having his or her routine blood and
      urine collection to monitor heart, liver or kidney function as part of his or her standard of
      care treatment at UCLA or UCSD and UCI. These routine blood collections are not included in
      the total blood for the study discussed above. The schedule for these routine blood and urine
      collection will depend on the subject's condition and will be at their treating physician's
      discretion.

      Adherence will be measured with daily medication diaries, the CleverCaps electronic pill
      bottle caps, and with the coefficient of variation of tacrolimus in subjects' blood.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to first occurrence of acute rejection, failure, death</measure>
    <time_frame>3 years post-transplant</time_frame>
    <description>The definition of graft failure includes re-transplant and/or death and in case of kidney transplant also includes return to dialysis. The definition of acute rejection in kidney transplant will be based on Banff 2007 classification, in heart transplant will be based on revised 2004 ISHLT grading and in liver transplant will be based on Banff schema for grading liver allograft rejection.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Graft Rejection at 1 year</measure>
    <time_frame>1 year post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft Rejection at 2 years</measure>
    <time_frame>2 years post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft Rejection at 3 years</measure>
    <time_frame>3 years post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft Failure at 1 year</measure>
    <time_frame>1 year post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft Failure at 2 years</measure>
    <time_frame>2 years post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft Failure at 3 years</measure>
    <time_frame>3 years post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Infectious Episodes at 1 year</measure>
    <time_frame>1 year post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Infectious Episodes at 2 years</measure>
    <time_frame>2 years post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Infectious Episodes at 3 years</measure>
    <time_frame>3 years post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Malignancy at 1 year</measure>
    <time_frame>1 year post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Malignancy at 2 years</measure>
    <time_frame>2 years post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Malignancy at 3 years</measure>
    <time_frame>3 years post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death or loss-to-follow-up at 1 year</measure>
    <time_frame>1 year post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death or loss-to-follow-up at 2 years</measure>
    <time_frame>2 years post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death or loss-to-follow-up at 3 years</measure>
    <time_frame>3 years post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activity of Nuclear Factor of Activated T Cells (NFAT) - dependent cytokine expression levels</measure>
    <time_frame>post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in lymphocyte subpopulations and production of donor specific HLA antibodies</measure>
    <time_frame>post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence with medication regimen</measure>
    <time_frame>post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life with Medication Regimen</measure>
    <time_frame>post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction with Medication Regimen</measure>
    <time_frame>post-transplant</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Renal Transplant Rejection</condition>
  <condition>Liver Transplant Rejection</condition>
  <condition>Cardiac Transplant Rejection</condition>
  <arm_group>
    <arm_group_label>Brand Tacrolimus Only : Prograf</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Arm 1 will receive brand tacrolimus for the entire study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Brand Tacrolimus for 6 months then switch to Generic A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Arm 2 will receive brand tacrolimus for the first 6 months and then receive specific generic tacrolimus for the remainder of the study.
Prograf followed by Tacrolimus.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Generic A Only</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Arm 3 will receive specific generic tacrolimus for the entire study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Generic A (6 months) then switch to Generic Tacrolimus</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Arm 4 will receive specific generic for the first 6 months,then receive unspecified generic tacrolimus as per their pharmacy covered by their own health insurance
Multiple Tacrolimus.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prograf</intervention_name>
    <description>Brand Drug for the duration of the study.</description>
    <arm_group_label>Brand Tacrolimus Only : Prograf</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prograf followed by Tacrolimus</intervention_name>
    <description>Brand followed by Generic Drug</description>
    <arm_group_label>Brand Tacrolimus for 6 months then switch to Generic A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Generic</description>
    <arm_group_label>Generic A Only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Multiple Tacrolimus</intervention_name>
    <description>Multiple Generic</description>
    <arm_group_label>Generic A (6 months) then switch to Generic Tacrolimus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed informed consent and or/assent

          2. Between the ages of 5 and 70 years, inclusive

          3. Able to swallow tablets and capsules

          4. Patients must be receiving primary or secondary kidney, pancreas, kidney/pancreas,
             liver, or heart allograft from a deceased donor, or for kidney allograft recipients, a
             non- HLA identical living donor

          5. Negative cross match test, and compatible (A, B, AB or O) blood type

          6. Patients must have no known contraindications to tacrolimus

          7. Women of childbearing potential (WOCBP) must have a negative pregnancy test WOCBP
             includes any female who has experienced menarche and who has not undergone successful
             surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral
             oophorectomy) or is not postmenopausal (defined as amenorrhea â‰¥ 12 consecutive months;
             or women on hormone replacement therapy with documented serum follicle stimulating
             hormone level &gt; 35 mIU/mL). Even women who are using oral, implanted, or injectable
             contraceptive hormones or mechanical products such as an intrauterine device or
             barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy or practicing
             abstinence or where the partner is sterile (e.g., vasectomy), should be considered to
             be of child bearing potential. WOCBP who are taking MMF must in addition use methods
             of birth control as stipulated in the package insert, namely: Either intrauterine
             device, or partner with vasectomy, or one hormone (oral contraceptive pill,
             transdermal patch, vaginal ring, or progesterone injection or implant) and one barrier
             method (diaphragm or cervical cap with spermicide, contraceptive sponge, or male or
             female condom), or two barrier methods as described above. WOCBP must have a negative
             serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human
             chorionic gonadotropin [HCG]) within 72 hours prior to the start of study medication
             then every 3 months during the period of study participation.

        Additional Eligibility Criteria:

          1. HCV, HBV, HIV positive subjects will be enrolled in non-liver recipient groups. It is
             not an exclusion criteria so these subjects could be enrolled.

          2. Liver transplant subjects will be included if they have a t tube as long they can
             swallow tablets/capsules and they are deemed suitable by the investigator.

          3. The use of azole antifungals is allowed.

          4. These agents (mTOR inhibitors) are not recommended but it would be determined by the
             subject's treating physician if they can be used.

        Exclusion Criteria:

          1. Those who receive simultaneous combined organ transplants except for simultaneous
             pancreas kidney transplant.

          2. Patients with clinically significant active infections (for example, those requiring
             hospitalization, or as judged by the Investigator) or malignancies

          3. Recipients who are concurrently receiving belatacept or anticipate to receive
             belatacept as part of their immunosuppressive regimen

          4. Patients currently enrolled in another investigational device or drug study

          5. WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for
             the entire study period

          6. Women who are breast-feeding or pregnant with a positive pregnancy test on enrollment
             or prior to study drug administration

          7. Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for
             treatment of either a psychiatric or physical (e.g., infectious disease) illness must
             not be enrolled into this study.

          8. Any psychiatric or medical that, in the investigator's opinion, may put the subject at
             significant risk, may confound the study results, or may interfere significantly with
             the subject's participation in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suphamai Bunnapradist, M.D.,M.S.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Oluwamurewa Oguntimein, M.H.S.</last_name>
    <phone>301-796-4869</phone>
    <email>oluwamurewa.oguntimein@fda.hhs.gov</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Janette Gadzhyan, B.S.</last_name>
    <phone>310-794-8516</phone>
    <email>jgadzhyan@mednet.ucla.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UCLA Kidney Transplant Research</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janette Gadzhyan, B.S.</last_name>
      <phone>310-794-8516</phone>
      <email>jgadzhyan@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Suphamai Bunnapradist, M.D., M.S.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joanna Schaenman, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Phuong-Thu Pham, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lum Erik, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 26, 2016</study_first_submitted>
  <study_first_submitted_qc>August 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2016</study_first_posted>
  <last_update_submitted>March 7, 2018</last_update_submitted>
  <last_update_submitted_qc>March 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Suphamai Bunnapradist</investigator_full_name>
    <investigator_title>Professor of Medicine, Director of Research</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

